The defining feature of the AI discourse at Reuters Pharma USA this week in Philadelphia was its specificity – while previous years and similar events have featured a lot of pan ...

The Innovation in Psychosis Therapeutics Summit is the leading industry event driving the next generation of psychosis drug ...

At the JP Morgan Healthcare Conference in January, pharmaphorum editor-in-chief Jonah Comstock caught up with Bradley Bostic, the co-founder, CEO, president, and chairman of h1c to talk about one such ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

While AZ is eyeing overseas expansion with its new investment, J&J has embarked on a reshoring drive with a pledge to invest ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...

Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...

Among the leading biotech organisations, innovators and solution providers joining the show, are Discovery Park, Thistle ...

Among the leading biotech organisations, innovators and solution providers joining the show, are Discovery Park, Thistle ...